Original Research Article

Molecular Cloning of Pyruvate Formate Lyase Gene of *Staphylococcus aureus* Associated with Bovine Mastitis

Varra Manasa¹*, T. Venkata Sai Kumar², T. Prasada Rao², K. Aswani Kumar³, J. Thanislass⁴ and V. Girish Kumar⁵

¹Department of VBC, Veterinary College, Hebbal, KVAFSU, India
²Department of VBC, C.V.Sc, PDTR, SVVU, India
³Department of VBC, N.T.R C.V.Sc, Gannavaram, SVVU, India
⁴Department of VBC, RIVER, Puducherry, India
⁵Department of VBC, Veterinary College, Hebbal, KVAFSU, India

*Corresponding author

Abstract

Pyruvate formate lyase (PFL) of *Staphylococcus aureus* is an important protein which gets expressed mainly as an adaptive response for their survival in the host mammary tissue by way of producing biofilm. This adaptive mechanism of *S. aureus* mainly contributes to sub-clinical, chronic bovine mastitis which often becomes challenging to treat with conventional antibiotics and thereby the prevention of further spread of infection in the herd becomes difficult. The present preliminary study is an attempt to clone and characterize 609 bp antigenic site of pyruvate formate lyase gene of *S. aureus* associated with bovine mastitis. The partial PFL gene cloned using TA cloning vector showed 98-99% identity with the reference sequence available in the Genbank (MK695632). The cloned insert with overhangs released by restriction enzyme digestion can be used to obtain the antigenic protein by using pET 32a+ expression vector system. The antibodies to pyruvate formate lyase were obtained in the serum of cows associated with *S. aureus* bovine mastitis which was as an important finding in Serological Proteome Analysis (SERPA). Therefore the protein expressed from the cloned partial PFL gene can be used for the development of immunoassay kit for early diagnosis and also as a vaccine candidate for the control and prevention of *S. aureus* associated bovine mastitis.

Keywords

*S. aureus*, Bovine mastitis, Pyruvate formate lyase gene (PFL gene), Cloning, Immunogenic protein

Article Info

Accepted: 07 November 2020
Available Online: 10 December 2020

Introduction

*S. aureus* is one of the main causative agents of bovine mastitis, the most economically important disease of dairy ruminants (Tesfaye *et al.*, 2010; Banerjee *et al.*, 2019). Among all the pathogens causing mastitis, *S. aureus* is of important concern because of its ability to cause chronic disease. Existence of Small Colony Variants (SCVs) of *S. aureus* and Methicillin Resistant *Staphylococcus aureus* (MRSA) among the *S. aureus* isolates of bovine mastitis is an increasing concern because of its zoonotic importance (Gopal and Divya, 2017; Gravel and Malouin, 2018; Atalla *et al.*, 2011). *S. aureus* also exhibits
resistance to antiseptics and disinfectants, such as quaternary ammonium compounds, which may aid its survival in the hospital environment. Biofilm associated S. aureus were found to exhibit innate resistance to antibiotics, disinfectants and clearance by host defenses (Aslantas and Demir, 2016).

*S. aureus* remains as one of the major disease causing organisms of contagious bovine mastitis due to its unique ability to escape the innate immune response such as phagocytic, complement or antimicrobial peptide (AMP)-mediated killing assisting its survival in blood and other tissues during chronic infections (Hensen et al., 2000; Gresham et al., 2000; Barrio et al., 2006; Zeccoli et al., 2006; Gunther et al., 2017). Many vaccines are commercially available against *S. aureus* associated with bovine mastitis, but are failing to give protective immunity except few trials which are successful at the herd level mostly (Annemuller et al., 1999; Fitzgerald et al., 1997; Saei et al., 2009).

Multiple factors account for the lack of protection, like the selection of vaccine targets, high diversity among mastitis-provoking strains, variation in immune response between animals and a failure to elicit an immune response that is required for protection against this complex intramammary pathogen (Gravel and Malouin., 2018). Therefore, this demands an urgent need for the development of alternative vaccines that either prevent infection or facilitate clearance of the bacteria from the mammary gland very shortly after intra mammary infection. This can not only help to prevent *S. aureus* bovine mastitis, but also to eliminate the possibility of chronic infection that can serve as a reservoir of infection to the herd-mates (Rainard et al., 2018).

The specific and general defense mechanisms of *S. aureus* are based on the sophisticated pathways of signal transduction, which subsequently trigger changes in gene expression (Falko et al., 2008). Tissue specific (udder and / or its secretions) gene expression studies of *S. aureus* may help to identify antimicrobials or drug targets that can effectively treat the *S. aureus* to overcome the existing problem of multidrug resistance. The expression of PFL gene was identified in the clinical isolates of *S. aureus* associated with bovine mastitis with the help of serological proteome analysis (SERPA) (Anitha et al., 2014). Puruvate formate lyase is an important protein involved in anaerobic glucose metabolism (Leibig et al., 2011).

The expression of PFL gene in *S. aureus* associated with bovine mastitis has been found to be mainly as an adaptive response for the survival of the organism through the formation of biofilm (Manasa et al., 2014). With this background, the present work was designed to clone and express this PFL gene of *S. aureus* associated with bovine mastitis in the process of either making a protein for use as vaccine or developing an immune assay kit for early diagnosis. The protein once obtained in bulk can also be used in studies for the identification of alternate and effective drugs that can inhibit this crucial enzyme necessary for survival of *S. aureus* in the udder tissue.

**Materials and Methods**

**Bacterial isolate**

The field strain of *Staphylococcus sp.* was initially isolated on Mueller Hinton agar with 7% sodium chloride which was then streaked on to Baird Parker agar supplemented with egg yolk emulsion and potassium tellurite solution (Hi media) for the identification of *S. aureus*. The field strains of *S. aureus* were then further confirmed by PCR for *S. aureus* by the amplification of nuc gene (Brakstad et al., 1992; Manasa et al., 2019).
**Primer designing**

The gene locus tag SACOL204 with the GI no. 57285406 was used for the designing of primers for the amplification of PFL gene of *S. aureus*. The position of the nucleotide sequence is from 239821- 242070. Artificial neural network based B-cell epitope prediction server (ABC pred server) was used to predict the antigenic sites in the full length gene of pflB. Using DNASTAR lasergenev6 software package and oligoanalyser, primers were designed for the amplification of 609 bp PCR product which contain the predictive antigenic sites. Restriction enzyme (RE) site for Bam HI was introduced while designing the reverse primer and RE site for Nco I was introduced while designing the forward primer (Table 1). These RE sites were introduced for the cloning of partial PFL gene using the TA cloning kit with one shot INVαF chemically competent *E. coli* from Invitrogen (K2000-01). The RE sites also serve an advantage of digesting the recombinant plasmids with the REs for the directional cloning and expression of partial PFL gene product which is predicted to be antigenic. The TA cloning vector used in the study and pET 32a+ selected for expression of PFL protein product are being represented in Fig. 1a and 1b. The primer specificity was checked by using primer-BLAST. The specific set of primers used in the cloning experiment was synthesized from Eurofins Genomics India Pvt. Ltd., Bangalore.

**Determining the specificity of primers designed**

The specificity of the primers designed was determined by performing PCR using the designed primers wherein the DNA isolated from field strains of *S. aureus* was used as the template. A 20 µl reaction mixture was prepared which contained 5.0 µl of DNA template (0.2 µg/µl), 1.0 µl of forward primer (10pmol/µl), 1.0 µl of reverse primer (10pmol/µl), 10.0 µl of Dream Taq green PCR master mix (2X) form Thermo scientific and 3.0 µl of nuclease free water. The amplification conditions standardized were as follows: an initial denaturation of 94ºC for 5 minutes; 30 cycles of 94ºC for 30 sec, 60ºC for 40sec and 72ºC for 40 sec and a final extension step at 72ºC for 5 min. The amplified gene product was confirmed for the expected amplicon size by agarose gel electrophoresis. The PFL gene product so obtained was then purified from the gel by using Thermo scientific Gene JET gel extraction kit. The purified PFL PCR product was then custom sequenced by Eurofins genomics India Pvt. Ltd, Bangalore. The sequence obtained was subjected for sequence analysis using BLAST. With the help of BLAST score and e-value, the specificity of the sequence was ascertained.

**Cloning of partial pflB gene in TA cloning vector**

Fresh PCR products of partial PFL gene (609bp) obtained from field isolates of *S. aureus* associated with bovine mastitis were ligated with the TA cloning vector by using manufacturer’s protocol with slight modifications. Pfu DNA Polymerase, recombinant (Thermo Scientific #EP0501) was used for obtaining the amplicons for the cloning experiment by setting up PCR reaction of 50 µl with manufacturers protocol with slight modifications using the same primers designed for cloning. Cloning of the partial PFL gene into the TA cloning vector involved the three basic steps: Ligation, transformation and plating which are as follows.

**Ligation:** A 10µl reaction was set up for ligation of amplified partial *pflB* gene with the above described TA cloning vector using 1µl each of PCR product and T4 DNA ligase.
enzyme, 2µl each of 5X T4 DNA ligase reaction buffer and TA cloning vector. The final volume was made to 10µl with nuclease free water. This ligation reaction was incubated at 37°C for 1hr and stored at 4°C overnight.

Transformation: Transformation was done by following the manufacturer’s protocol with slight modifications and by using the INVαF competent E. coli cells provided in the kit and also by using DH5α cells. Water bath was equilibrated to 42°C and SOC medium was brought to room temperature. X-gal (40mg/ml) was added to the prepared LB agar plates with ampicillin (0.1g/ml). The competent cells were thawed on ice for transformation. The ligation reaction was also kept on ice. 2µl each of ligation reaction was directly added to the vials of competent cells. The vials were incubated on ice for 30min. Transformation was aided by subjecting the cells to heat shock at 42°C for 30 sec. The vials were immediately transferred to ice. 250 µl of SOC medium was added to each vial. The vials were then incubated in a horizontal shaker at 37°C for 1 hr at 225 rpm.

Plating: 50 µl of transformation mix was then plated on to the LB agar plates containing ampicillin. The plates were then incubated overnight at 37°C for obtaining the recombinant clones. The same procedure mentioned above was used for transformation of ligation reaction into DH5α cells (with slight modifications) excepting that there was addition of IPTG (100mM) to the LB agar media at the final concentration of 1mM.

Screening of recombinant clones

The identification of the recombinant clones was done by employing all the possible methods which included the blue white screening, colony PCR, plasmid PCR, sequence analysis of insert in the recombinant (r) clones and restriction enzyme (RE) analysis of r clones which are briefly described as follows:

Blue-white screening: The recombinant plasmids were screened by the visual identification of white colonies on the LB agar plates upon incubation with the transformed cells. White colonies actually represent the insertion of gene of insert into the vector and thereby the disruption of the lacZ coding for the β galactosidase whose substrate is X-gal.

Colony PCR: A 25 µl reaction was set up with 12.5 µl of Dream taq green PCR master mix (Thermo Scientific), 1 µl of forward primer, 1 µl of reverse primer, a portion of transformed colony (white) as template and 10.5 µl of nuclease free water. Amplification was carried out by using PCR conditions standardized above for the amplification of partial pfIB gene of S. aureus.

Plasmid PCR: In order to perform the plasmid PCR, recombinant DNA was isolated from the transformed cells (white colonies) after inoculating into 1.5ml luria broth with ampicillin and incubation at 37°C overnight. The isolation of plasmid was then carried out by alkaline lysis method with minor modifications (Behle., 2017). The plasmid pellet obtained was then reconstituted with 20-30 µl of TE buffer. Plasmid PCR was then performed using the isolated recombinant DNA as a template for PCR.

Sequence analysis of insert in the recombinant (r) clones: For the further confirmation of the sequence specificity of partial pfIB gene insert in the recombinant plasmid, the plasmids were gel extracted and purified which were then custom sequenced by Eurofins Genomics India Pvt. Ltd., Bangalore. The sequences obtained were then subjected for sequence analysis using
BLAST. With the help of BLAST score and e-value, the specificity of the insert sequence in the TA cloning vector was ascertained.

**Restriction enzyme analysis of r clones**

The insert was then released from the recombinant plasmid by digesting with Nco I (Thermoscientific) using manufacturers’ protocol with slight modification. The size of the Nco I digested recombinant plasmid (pCR2.1) in comparison with the 1Kb plus ladder was ascertained. The band corresponding to 3000 Kb was gel extracted and purified, the resultant purified product was then subjected for Bam HI (Thermo Scientific) digestion using manufacturers’ protocol with slight modification. The insert obtained as a result of sequential Nco I and Bam HI digestion was then gel purified and stored at -80°C for cloning and expressing the partial pflB gene in the directional expression vector.

**Results and Discussion**

The *S. aureus* field strain isolated on Baird Parker agar characterized by the appearance of black colonies surrounded by a clear zone is depicted in Fig. 2. Further confirmation of *S. aureus* by PCR resulted in the amplification of 270bp nuc gene specific to *S. aureus*. The specificity of primers designed for the amplification of partial PFL gene of *S. aureus* intended for initial cloning in the TA cloning vector and further expression in pET32a+ vector system resulted in the specific amplification of 609bp PCR product (Fig. 3). The sequenced PCR product also revealed 99-100% identity with the *S. aureus* PFL gene sequences available in the gene bank upon BLAST analysis.

Cloning of the partial PFL gene into the TA cloning vector was successful which was evinced by the white colonies obtained in the cloning experiment indicating the successful uptake of recombinant DNA by the competent cells (Fig. 4). Colony PCR resulted in the 609 bp PCR product which indicated the presence of desired gene (partial PFL gene) in the vector (Fig. 5). Isolation of recombinant plasmid by modified alkaline lysis method resulted in good yield and plasmid PCR resulted in the 609 bp PCR product which further confirmed the presence of desired gene (partial PFL gene) in the vector (Fig. 6a and 6b). The PFL gene sequences of the recombinant plasmid obtained after custom sequencing by Eurofins Genomics India Pvt. Ltd., upon subjecting to BLAST analysis showed 98-99 % identity with the reference sequences. One of the sequences obtained was submitted to the Genbank (BankIt), NCBI and the sequence was acknowledged with BankIt 2207221-Seq1- MK695632. RE digestion of the recombinant plasmids resulted in the specific bands. When digested with NcoI we obtained two bands corresponding to 3000Kb and 1500 Kbp respectively (Sites for NcoI: one in the insert and the other in the Kanamycin resistance ORF) (Fig. 7). Further digestion with Bam HI lead to the release of the cloned insert with overhangs. This insert with overhangs was gel extracted, purified and stored at -80 °C for further expression of the protein using PET 32a+ system as stated earlier.

Most of the vaccines in use for *S. aureus* bovine mastitis are given in the parenteral route. But the existence of blood-udder barrier between the systemic circulation and the udder tissue may result in insufficient levels of immune cells and antibodies at the site of infection. Therefore, alternative immunization routes and adjuvant formulations have been suggested in an attempt to increase the local immunity (Coffman et al., 2010; Holmgren et al., 2005; Pulendran et al., 2001). Inducing local antibody production in the udder ancillary to translocation of antibodies from...
serum and parental immunization might enhance the antibody levels in the milk (Butler et al., 2015; Boerhout et al., 2015; Boerhout et al., 2018).

**Table.1** Oligonucleotide primers designed for the amplification of Partial PFL gene containing the predicted antigenic site

<table>
<thead>
<tr>
<th>Primer</th>
<th>Target gene</th>
<th>Primer sequence (5’→ 3’)</th>
<th>Restriction site</th>
<th>Amplicon size</th>
</tr>
</thead>
<tbody>
<tr>
<td>NcoI PFL Forward</td>
<td>Partial PFL gene containing the predicted antigenic site</td>
<td>GCCCATGGATAATGATGACATTATGCGTGAAAG</td>
<td>NcoI</td>
<td></td>
</tr>
<tr>
<td>BamHI-PFL Reverse</td>
<td></td>
<td>GCGGATCCTATTGTATGTTCTGATCACG</td>
<td>BamHI</td>
<td>609bp</td>
</tr>
</tbody>
</table>

**Fig.1a** Schematic representation of the linearized vector, pCR2.1 used for the cloning of partial PFL gene shown below along with the multiple cloning sites (MCS)

**Fig.1b** Schematic representation of pET 32a+ vector chosen for the expression of partial PFL gene product
**Fig. 2** Field strain of *S. aureus* associated with bovine mastitis on Baird parker agar showing black colonies indicating tellurite reduction, surrounded by a clear zone indicating lecithinase production.

**Fig. 3** PCR amplification of partial PFL gene of *S. aureus* associated with bovine mastitis with the use of primers designed intended for cloning and expression.

Lanes 4 and 8: Specific amplicons of 609 bp of partial PFL gene of *S. aureus*; Lane 10: Molecular weight ladder.

**Fig. 4** Transformation of *E.coli* DH5α cells with the ligated partial PFL gene of *S. aureus*.

White colonies representative of the recombinant plasmids with the insert are marked on the plate in red for performing colony PCR and plasmid PCR.
**Fig. 5** Colony PCR amplification of transformed *E. coli* DH5α cells with recombinant plasmids

Lanes 1, 2, and 3: white colonies as template; Lane 4: positive control; Lane 5: 100bp DNA ladder; Lane 6: no template control

**Fig. 6a** Plasmid isolation by modified alkaline lysis method

Lanes 2, 3, 4 and 5: Recombinant plasmids isolated by modified alkaline lysis method, Lane 6: 100bp DNA ladder

**Fig. 6b** Plasmid PCR

Lanes 3, 4 and 6: 609 bp amplicon of inserted partial PFL gene of *S. aureus* of the recombinant plasmid taken up by the competent cells by transformation
As the infections caused by *S. aureus* are multi-drug-resistant, active immunization, the use of novel antibody-based passive immunization strategies might offer a hope in showing enhanced efficacy in the vaccination trails as a part of the development of an effective therapeutic approach (Ansari *et al.*, 2019). Experimental immunization of young heifers with staphylococcal immune evasion molecules, Extracellular fibrinogen-binding protein (*Efb*), Leukocidin subunit M (*LukM*) resulted in an immune response different from that induced by natural exposure to *S. aureus*, leading to significantly higher antibodies specific for *S. aureus* immune evasion factors locally in the udder (Benedictus *et al.*, 2019).

Also, *in vitro* studies with nano-scale materials such as silver nanoparticles in combination with existing antibiotics have emerged as novel antimicrobial agents to treat infections caused by multi-drug-resistant organisms (Morones *et al.*, 2005; Rai *et al* 2008; Duran *et al.*, 2010; Ruden *et al.*, 2009; Thirumurugan *et al.*, 2016; Kora and Rastogi., 2013). Autophagy is found to occur in *S. aureus*-infected bovine macrophages but is blocked at a later stage of autophagy. The accumulation of autophagosomes was found to facilitate the survival of *S. aureus* in bovine macrophages (Cai *et al.*, 2020). *S. aureus* was found to induce autophagy in bovine macrophages, which actually is a cellular homeostatic mechanism in eukaryotes aiding for survival during cellular stress. It is also regarded as a host defence mechanism that contributes to the degradation of intracellular pathogens (Neumann *et al.*, 2016; Wileman 2013). Understanding of the detailed molecular mechanism of how *S. aureus* escape bovine macrophages by autophagic flux to survive in them may provide alternate solutions for targeted therapy.

Recent *in vivo* research explored to unravel the adaptive mechanisms of *S. aureus* associated with bovine mastitis contributing to chronic, sub-clinical and recurrent udder infections revealed the following interesting findings. *S. aureus* was found to evolve itself within the udder by exhibiting *Sigma factor B* (*SigB*) – deficient pathotype characterized by enhanced proteolytic activity and Poly-N-acetylglucosamine (PNAG) based biofilm production, but reduced virulence (Marbach *et al.*, 2019).
Therefore, the present study is a way forward as one of the alternative attempts to combat *S. aureus* associated bovine mastitis by choosing antigenic site of pyruvate formate lyase as a protein for vaccine preparation, developing an immune assay kit for early diagnosis of subclinical mastitis or for the identification of alternate and effective drugs for the arrest of the growth of the bacteria. Once the purified protein is in hand after expression of partial PFL gene in pET 32a+ vector system, passive immunization with antibodies (produced against this protein) locally in the udder can also be thought of as an alternate option in attempt to enhance the host immune response in the udder or to arrest the growth of the biofilm forming *S. aureus*.

**Acknowledgement**

The authors are thankful to Sri Venkateswara Veterinary University, India for providing financial assistance to carry out this research work.

**References**


Barrio, M.B., P. Rainard and G. Prevost. 2006. LukM/LukF-PV is the most active Staphylococcus aureus leukotoxin on bovine neutrophils. *Microbes Infec.:* 8: 2068-74


How to cite this article: